

HAVCR2 protein inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/H473228F68FAEN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: H473228F68FAEN

Abstracts

This report can be delivered to the clients within 3-4 Business Days

DelveInsight's, "HAVCR2 protein inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 8+ companies and 9+ pipeline drugs in HAVCR2 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

HAVCR2 protein inhibitors Understanding

HAVCR2 protein inhibitors: Overview

Hepatitis A virus cellular receptor 2 (HAVCR2), also known as T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), is a protein that in humans is encoded by the HAVCR2 (TIM-3) gene. HAVCR2/TIM-3 is a transmembrane protein of T lymphocytes (CD4+ and CD8+ T cells), myeloid cells (monocytes, macrophages, DC, mast cells, NK cells) or various cells in different tumor types. The receptor is an immune checkpoint and together with other inhibitory receptors including programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 protein (LAG3) mediate the CD8+ T-cell exhaustion in terms of proliferation and secretion of cytokines such as TNF-alpha, IFN-gamma and IL-2. Combined blockade of HAVCR2 and PD-1 led to improved CD8+ T-cell response during the lymphocytic choriomeningitis virus infection.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence HAVCR2 protein inhibitors R&D. The therapies under development are focused on novel approaches for HAVCR2 protein inhibitors.

HAVCR2 protein inhibitors Emerging Drugs Chapters

This segment of the HAVCR2 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

HAVCR2 protein inhibitors Emerging Drugs

Sabatolimab: Novartis

Sabatolimab (MBG 453) is an anti T-cell immunoglobulin and mucin domain 3 (anti-TIM3) monoclonal antibody that is being developed by Novartis Oncology. Sabatolimab is a first-in-class investigational immuno-myeloid therapy that binds to TIM-3, a novel target expressed on multiple immune cell types and leukemic cells and blasts, but not on the normal stem cells that induce blood formation; it is in development for HR-MDS and acute myeloid leukemia (AML).

BMS 986258: Bristol-Myers Squibb

BMS 986258 (also known as ONO 7807) is a fully-human monoclonal antibody targeting T-cell immunoglobulin and mucin domain-3 (TIM-3 or HAVCR2) developed by Bristol-Myers Squibb. Currently, it is in Phase II stage of clinical trial evaluation to treat Solid tumours.

Further product details are provided in the report.....

HAVCR2 protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different HAVCR2 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on HAVCR2 protein inhibitors

There are approx. 8+ key companies which are developing the HAVCR2 protein inhibitors. The companies which have their HAVCR2 protein inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Novartis.

Phases

DelveInsight's report covers around 9+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

HAVCR2 protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

HAVCR2 protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I,

preclinical and discovery stage. It also analyses HAVCR2 protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HAVCR2 protein inhibitors drugs.

HAVCR2 protein inhibitors Report Insights

HAVCR2 protein inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

HAVCR2 protein inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing HAVCR2 protein inhibitors drugs?

How many HAVCR2 protein inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of HAVCR2 protein inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the HAVCR2 protein inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for HAVCR2 protein inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Novartis

Bristol-Myers Squibb

BrightPath Biotherapeutics

Symphogen

Aurigene Discovery Technologies

Incyte Corporation

Eli Lilly and Company

AnaptysBio

Key Products

Sabatolimab

BMS 986258

BP 1210

Sym 023

MAS 825

CA 327

INCAGN 02390

LY 3415244

Cobolimab

Contents

Introduction

Executive Summary

HAVCR2 protein inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

HAVCR2 protein inhibitors – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Sabatolimab: Novartis

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

BMS 986258: Bristol-Myers Squibb

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

LY 3415244: Eli Lilly and Company

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis
CA 327: Aurigene Discovery Technologies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
Comparative Analysis
HAVCR2 protein inhibitors Key Companies
HAVCR2 protein inhibitors Key Products
HAVCR2 protein inhibitors- Unmet Needs
HAVCR2 protein inhibitors- Market Drivers and Barriers
HAVCR2 protein inhibitors- Future Perspectives and Conclusion
HAVCR2 protein inhibitors Analyst Views
HAVCR2 protein inhibitors Key Companies
Appendix

I would like to order

Product name: HAVCR2 protein inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/H473228F68FAEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H473228F68FAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970